Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries

• Main Authors: Hyun Kyeong Yoo (Author), Han Geul Byun (Author), Flavio Caprioli (Author), Mathurin Fumery (Author), Laurent Peyrin-Biroulet (Author), Subramanian Sreedhar (Author), James Potter (Author), Minyoung Jang (Author)
• Format: Book
• Published: BMC, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background In 2020, the European Medicines Agency approved infliximab subcutaneous (SC) for the treatment of inflammatory bowel disease. This new mode of infliximab administration will reduce outpatient visits and costs of intravenous (IV) administration. This article describes a budget imp...